Back to results
US 10,744,170 B2Granted
Combination treatment
AssigneeDuke University
InventorsDarell D. Bigner, Matthias Gromeier, Smita Nair, Vidyalakshmi Chandramohan
Life of this patent
Estimating the term…
Abstract
Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Combination with immune checkpoint inhibitors increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioglastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.
Claims27
A method of treating a tumor in a patient to achieve a therapeutic anti-tumor effect, wherein the tumor expresses NECL5 (nectin-like protein 5), comprising:
- administering to the patient a chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5′ untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame;
- and
- administering an immune checkpoint inhibitor to the patient, whereby the patient is treated.
Dependencies are inferred from the claim text.